Respiratory Motion, Inc. is excited to announce the FDA clearance for the ExSpiron™ 1Xi Minute Ventilation monitor for the use in Pediatric Patients

· Minute Ventilation (MV) is the earliest indicator of insufficient breathing. The ExSpiron is the first and only MV monitor capable of providing continuous, non-invasive measurements for individuals not on a ventilator.

Respiratory Motion, Inc. (Waltham, Massachusetts, USA) reported today that FDA clearance was received for the newest version of its ExSpiron Minute Ventilation (MV) monitoring system on Friday March 16th and announced its plan to launch the new ExSpiron at the Society for Pediatric Anesthesia-American Academy of Pediatrics in Phoenix, March 23-25.

Respiratory failure can occur anywhere in the hospital and early detection can often make the difference between life and death. MV monitoring is the most direct measure of respiratory status, providing the earliest warning of changes in respiratory status. Sufficient time to act is crucial in preventing bad outcomes. Respiratory Motion’s ExSpiron is the first and only continuous Minute Ventilation Monitor that has been cleared for broad use in hospital and ancillary medical settings.

See the full release here.

Member Login
Welcome, (First Name)!

Forgot? Show
Log In
Enter Member Area
My Profile Not a member? Sign up. Log Out